Key clinical point: Real-world data shows that the recombinant factor IX product nonacog alfa is safe and effective for patients with hemophilia B.
Major finding: Effectiveness rates were 95.5% and 93.7% for patients who received routine prophylaxis and on-demand treatment, respectively.
Study details: A postmarketing surveillance study of 312 patients with hemophilia B.
Disclosures: The study was funded and conducted by Pfizer Japan. The authors reported financial relationships with Pfizer and several other companies. One coauthor is an employee of Pfizer Japan.
Fukutake K et al. Haemophilia. 2019 Jun 6. doi: 10.1111/hae.13783